Market focus Target hospitals and orthopedic centers that prioritize meniscal preservation to expand adoption of NovoStitch Pro, emphasizing joint health long-term outcomes to drive surgeon interest.

Expansion narrative Leverage past acquisition by Smith & Nephew as a credibility signal and explore partnerships or distribution opportunities that align with larger orthopedic portfolios seeking advanced meniscal repair capabilities.

Clinical impact Highlight the device’s ability to repair complex tears (horizontal, radial, root) to address current treatment gaps and reduce progression to arthritis, offering a compelling value proposition for surgeons and payers.

Financial leverage With revenue in the low single digits to mid-range, position NovoStitch Pro as a high-value, cost-effective upgrade for facilities aiming to differentiate its arthroscopy offerings and potentially improve reimbursement outcomes.

Growth signals Note prior product launch momentum in 2018 and ongoing regulatory/quality posture (ISO, HIPAA, Salesforce usage) to reassure potential partners of scalable, compliant operations and a clear path to wider adoption.